Table 1.
Anti-proliferative activity of TAE226 against cancer cell lines
| Cell origin | Cell line name | GI50 (μM) | n |
|---|---|---|---|
| Breast | MCF-7 | 1.2 ± 0.22 | 7 |
| MCF-7/ADR-RES | 1.1 ± 0.23 | 4 | |
| MDA-MB-231 | 0.56 ± 0.22 | 3 | |
| MDA-MB-435 | 1.6 ± 0.044 | 3 | |
| MDA-MB-453 | 1.5 ± 0.32 | 3 | |
| 4T1 | 0.16 ± 0.022 | 5 | |
| MTF7 | 1.4 ± 0.26 | 3 | |
| Prostate | DU145 | 0.23 (0.20, 0.25) | 2 |
| PC-3/M | 0.83 ± 0.29 | 4 | |
| Lung | NCI-H23 | 0.29 (0.24, 0.35) | 2 |
| NCI-H460 | 0.40 ± 0.028 | 4 | |
| LLC | 0.13 ± 0.0077 | 4 | |
| Colon | COLO205 | 0.21 (0.11, 0.30) | 2 |
| HCT-15 | 0.71 ± 0.1 | 5 | |
| HCT-116 | 0.42 ± 0.056 | 3 | |
| SW620 | 0.51 ± 0.024 | 3 | |
| WiDr | 0.14 ± 0.030 | 5 | |
| Stomach | KATOIII | 0.54 ± 0.064 | 3 |
| Pancreas | BxPC-3 | 0.53 ± 0.11 | 3 |
| MIA PaCa-2 | 0.26 ± 0.062 | 4 | |
| PANC-1 | 3.6 ± 0.93 | 3 | |
| SUIT-2 | 0.18 ± 0.029 | 3 | |
| Glioma | A172 | 1.6 (2.2, 1.1) | 2 |
| DBTRG-05MG | 0.47 ± 0.054 | 3 | |
| LN-18 | 0.96 ± 0.12 | 3 | |
| LN-229 | 0.56 ± 0.043 | 3 | |
| T98G | 0.42 (0.21, 0.63) | 2 | |
| U-87 MG | 1.0 (1.1, 0.97) | 2 | |
| U-118 MG | 1.3 (0.69, 1.8) | 2 | |
| U-373 MG | 1.4 (0.72, 2.0) | 2 | |
| Melanoma | A375M | 0.29 (0.15, 0.43) | 2 |
| C32 | 1.8 ± 0.31 | 3 | |
| C8161 | 0.90 (0.68, 1.1) | 2 | |
| SK-MEL-23 | 0.17 ± 0.0090 | 3 | |
| SK-MEL-93 | 0.25 ± 0.050 | 4 | |
| WM1158 | 0.33 ± 0.099 | 3 | |
| Myeloma | RPMI8226 | 0.33 ± 0.060 | 3 |
TAE226 concentrations causing 50% inhibition of net cell growth (GI50) are given. Results are expressed as mean ± SEM (except experiments with n = 2 where 2 individual values are included). Cell growth was assessed by sulforhodamine B staining for adhesive cell lines and by AlamarBlue for suspension cell lines. GI50 values were calculated after 48 h treatment with TAE226